chartexchange

Five-year data of continuous Leqembi® treatment show increasing benefit over time

Cision | Nov 16, 2026 6:05 PM EST

Stockholm, Sweden, November 17, 2026 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new five-year data from the Clarity AD study and its long-term extension, showing increasing clinical benefit with continuous Leqembi treatment in early Alzheimer’s disease. The data, presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, also showed that 62 percent of patients treated at an earlier stage of disease, with low levels of tau, showed improvement in cognitive function and activities of daily living (CDR-SB[1]), after five years.

Read original article